Tech Company Financing Transactions
MacroGenics Funding Round
MacroGenics secured a $45 million Series C funding round on 5/17/2006. Investors included Alta Partners, InterWest Partners and MPM Capital.
Transaction Overview
Company Name
Announced On
5/17/2006
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series C
Investors
Proceeds Purpose
We are planning to use a significant portion of the money to support an international Phase 2/3 trial of MacroGenics' lead product candidate, a CD3 monoclonal antibody (Mab) for Type 1 diabetes mellitus and to advance treatments for other autoimmune diseases such as arthritis and multiple sclerosis.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9640 Medical Center Dr.
Rockville, MD 20850
USA
Rockville, MD 20850
USA
Phone
Website
Email Address
Overview
MacroGenics is a private, venture-backed biotechnology company headquartered in Rockville, Maryland that focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Scott Koenig
Chief Financial Officer
James Karrels
Controller
Lynn Cilinski
VP - Bus. Development
Eric Risser
VP - R & D
Ezio Bonvini
Browse more venture capital transactions:
Prev: 5/16/2006: Zopa venture capital transaction
Next: 5/17/2006: GridPoint venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document every notable VC transaction. VC transactions on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs